Surrozen, Inc.
corporate_fare Company Profile
Surrozen, Inc. (NASDAQ:SRZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for SRZN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for SRZN spans 10-Q, 8-K, SCHEDULE 13D/A, 424B5.
Recent high-impact activity:
- Surrozen Raises $60M in Stock Sale at 1.2% Discount to Thursday's Close
- Surrozen Q3: $129.7M Non-Cash Loss, Boehringer Arbitration Disclosed, Cash Into 2029
- Surrozen Q3: DUET Phase 2a Expanded to 150 Patients, Cash Runway Into 2029
- Surrozen Posts $129.7M Q3 Net Loss as Operating Expenses Hit $17.6M
- Surrozen Closes $95.1M Final Tranche, Extends Cash Runway Into 2029
Financial Snapshot
Short Interest & Short Volume
8.51 days to coverFINRA reported short interest of 3,234,984 shares in SRZN as of the October 30, 2026 settlement, a 3.3% increase from the prior period — about 8.5 days to cover at its recent average daily volume. On November 20, 2026, 52.7% of SRZN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for SRZN, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.
Offering Terms Unchanged From Pricing · Net Proceeds and Fees
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →